A Phase 2b, Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy.

Trial Profile

A Phase 2b, Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Atrasentan (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 22 Aug 2017 Results of longitudinal assessments of effects of atrasentan on thoracic bioimpedance published in the Drugs in R and D
    • 26 Jul 2017 Results (n=257) of this and 2 other phase II studies, published in the Clinical Therapeutics.
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top